Next-generation antifungal therapeutics: emerging drug targets, precision strategies, and novel treatment modalities

Invasive fungal infections (IFIs) remain a major global health threat, particularly among immunocompromised patients. Current antifungals that target ergosterol biosynthesis, cell-wall assembly, and nucleic-acid synthesis are increasingly constrained by toxicity, drug-drug interactions, suboptimal pharmacokinetics, narrow spectra, and rising resistance. This review provides the transition from conventional antifungal agents to a next-generation, precision-oriented therapeutic landscape. In Part I, we expand the antifungal target repertoire beyond classical pathways to include emerging molecular nodes. Part II outlines principles for precision antifungal therapeutics, distinguishing pathogen-specific from broad-spectrum approaches and species-tailored regimens, and integrates rapid diagnostics into companion diagnostic frameworks. Part III surveys advanced therapeutic platforms, encompassing antifungal peptides, antibody-based agents, nucleic acid therapeutics, and engineered probiotic strategies. Part IV highlights drug-delivery innovations, including liposomal and nanoparticle carriers, stimuli-responsive systems, antibody- and ligand-targeted constructs, formulations optimized for biofilm penetration and intracellular delivery, and phage-inspired delivery, with AI-assisted design accelerating formulation optimization. Part V synthesizes combination strategies. Together, these advances define a conceptual framework for precision antifungal medicine that integrates pathogen profiling, host factors, pharmacogenomics, therapeutic drug monitoring, and multi-omics data to individualize therapy, overcome resistance, improve selectivity, and enhance clinical outcomes in IFIs.

Authors

Institutions

Publication Details

Journal
Frontiers in Cellular and Infection Microbiology
Published
2026-11-19
DOI
https://doi.org/10.3389/fcimb.2026.2000007
Primary Topic
Antifungal resistance and susceptibility
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Next-generation antifungal therapeutics: emerging drug targets, precision strategies, and novel treatment modalities

Yeo-jin Kim, Ki-Young Kim, Ji-Hyun Yoon
Frontiers in Cellular and Infection Microbiology
Antifungal resistance and susceptibility
article

Next-generation antifungal therapeutics: emerging drug targets, precision strategies, and novel treatment modalities

Yeo-jin Kim, Ki-Young Kim, Ji-Hyun Yoon
article en

Abstract

Invasive fungal infections (IFIs) remain a major global health threat, particularly among immunocompromised patients. Current antifungals that target ergosterol biosynthesis, cell-wall assembly, and nucleic-acid synthesis are increasingly constrained by toxicity, drug-drug interactions, suboptimal pharmacokinetics, narrow spectra, and rising resistance. This review provides the transition from conventional antifungal agents to a next-generation, precision-oriented therapeutic landscape. In Part I, we expand the antifungal target repertoire beyond classical pathways to include emerging molecular nodes. Part II outlines principles for precision antifungal therapeutics, distinguishing pathogen-specific from broad-spectrum approaches and species-tailored regimens, and integrates rapid diagnostics into companion diagnostic frameworks. Part III surveys advanced therapeutic platforms, encompassing antifungal peptides, antibody-based agents, nucleic acid therapeutics, and engineered probiotic strategies. Part IV highlights drug-delivery innovations, including liposomal and nanoparticle carriers, stimuli-responsive systems, antibody- and ligand-targeted constructs, formulations optimized for biofilm penetration and intracellular delivery, and phage-inspired delivery, with AI-assisted design accelerating formulation optimization. Part V synthesizes combination strategies. Together, these advances define a conceptual framework for precision antifungal medicine that integrates pathogen profiling, host factors, pharmacogenomics, therapeutic drug monitoring, and multi-omics data to individualize therapy, overcome resistance, improve selectivity, and enhance clinical outcomes in IFIs.

Frontiers in Cellular and Infection MicrobiologyVol. 16
Kyung Hee University (KR), Sungkyul University (KR)
Antifungal resistance and susceptibility
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon